Field Title Intervention/treatment Phase Status Registration number Ref. Vaccination Safety and immunogenicity study of 2019-nCoV vaccine (mRNA-1273) for prophylaxis of SARS-CoV-2 infection (COVID-19) mRNA-1273 which targets the spike (S) protein of the coronavirus Phase 1 Recruiting NCT04283461 [53 ] A study of a candidate COVID-19 vaccine Adenovirus vaccine vector Phase 2 Recruiting NCT04324606 [54 ] Safety, tolerability, and immunogenicity of INO-4800 for COVID-19 in healthy volunteers INO-4800 Phase 1 Recruiting NCT04336410 [55 ] Application of BCG vaccine for immune-prophylaxis among Egyptian healthcare workers during the pandemic of COVID-19 Intradermal injection of BCG vaccine Phase 3 Not yet recruiting NCT04350931 [56 ] BCG vaccination to protect healthcare workers against COVID-19 (BRACE) BCG vaccine Phase 3 Recruiting NCT04327206 [57 ] BCG vaccine for healthcare workers as defense against COVID 19 (BADAS) BCG vaccine Phase 4 Recruiting NCT04348370 [58 ] A clinical trial to determine the safety and immunogenicity of healthy candidate MERS-CoV vaccine (MERS002) ChAdOx1 MERS Phase 1 Recruiting NCT04170829 [59 ] Safety and immunogenicity of a candidate MERS-CoV vaccine (MERS001) ChAdOx1 MERS Phase 1 Recruiting NCT03399578 [60 ] Safety and immunity of COVID-19 aAPC vaccine Pathogen-specific artificial antigen presenting cells (aAPC) Phase 1 Recruiting NCT04299724 [61 ] Immunity and safety of COVID-19 synthetic minigene vaccine Injection and infusion of lentiviral-SMENP-dendritic cells vaccine and antigen-specific cytotoxic T lymphocytes Phase 2 Recruiting NCT04276896 [62 ] A phase II clinical trial to evaluate the recombinant vaccine for COVID-19 (adenovirus vector) (CTII-nCoV) Recombinant novel coronavirus vaccine (adenovirus type 5 vector) Phase 1/2 Active, not recruiting NCT04341389 [63 ] Phase Ib-II trial of dendritic cell vaccine to prevent COVID-19 in frontline healthcare workers and first responders Autologous dendritic cells loaded with antigens from SARS-CoV-2, with or without granulocyte-macrophage colony-stimulating factor Phase 1/2 Not yet recruiting NCT04386252 [64 ] Study of safety and immunogenicity of BVRS-GamVac Adenoviral-based vaccine against MERS-BVRS-GamVac Phase 1/2 Recruiting NCT04130594 [65 ] Randomized, double-blind, placebo-controlled phase Ib study to assess the safety and immunogenicity of MVA-MERS-S_DF-1 MVA-MERS-S_DF1-low and high doses Phase 1 Not yet recruiting NCT04119440 [66 ] Study of safety and immunogenicity of BVRS-GamVac-Combi Heterologous adenoviral-based vaccine against MERS-BVRS-GamVac-Combi Phase 1/2 Recruiting NCT04128059 [67 ] Performance evaluation of BCG vaccination in healthcare personnel to reduce the severity of SARS-CoV-2 infection BCG vaccine Phase 3 Not yet recruiting NCT04362124 [68 ] A trial investigating the safety and effects of four BNT162 vaccines against COVID-2019 in healthy adults Four prophylactic SARS-CoV-2 RNA vaccines: BNT162a1, BNT162b1, BNT162b2, and BNT162c2 Phase 1/2 Recruiting NCT04380701 [69 ] Study to describe the safety, tolerability, immunogenicity, and potential efficacy of RNA vaccine candidates against COVID-19 in healthy adults Four prophylactic SARS-CoV-2 RNA vaccine candidates against COVID-19: BNT162a1, BNT162b1, BNT162b2, and BNT162c2 Phase 1/2 Recruiting NCT04368728 [70 ] Tableted COVID-19 therapeutic vaccine (COVID-19) Once-daily pill of therapeutic vaccine made from heat-inactivated plasma from donors with COVID-19 Phase 1/2 Recruiting NCT04380532 [71 ] Phase I study of a vaccine for severe acute respiratory syndrome (SARS) A recombinant DNA vaccine, VRC-SRSDNA015-00-VP Phase 1 Completed NCT00099463 [72 ] Cell therapy systems Bone marrow-derived mesenchymal stem cell treatment for severe patients with coronavirus disease 2019 (COVID-19) Bone marrow-derived mesenchymal stem cell Phase 1/2 Not yet recruiting NCT04346368 [73 ] Monocytes and NK cells activity in COVID-19 patients Study of immune-mediated mechanisms in patients tested positive for SARS-CoV-2 — Recruiting NCT04375176 [74 ] Immune cells in inflammatory arthritis with coronaviruses, including COVID-19 SARS virus, 40 ml blood sample — Not yet recruiting NCT04363047 [75 ] Safety and efficacy of intravenous Wharton’s jelly-derived mesenchymal stem cells in acute respiratory distress syndrome due to COVID 19 Wharton’s jelly-derived mesenchymal stem cells Phase 1/2 Not yet recruiting NCT04390152 [76 ] Convalescent plasma therapy Convalescent plasma compared to the best available therapy for the treatment of SARS-CoV-2 pneumonia (COP-COVID-19) Plasma Phase 2 Not yet recruiting NCT04358783 [77 ] Anti-SARS-CoV-2 inactivated convalescent plasma in the treatment of COVID-19 — — Recruiting NCT04292340 [78 ] Collection of anti-SARS-CoV-2 immune plasma (NIAID) — — Recruiting NCT04344977 [79 ] Inactivated convalescent plasma as a therapeutic alternative in patients COVID-19 Inactivated convalescent plasma Phase 2 Not yet recruiting NCT04385186 [80 ] Convalescent plasma for patients with COVID-19: a pilot study (CP-COVID-19) Plasma Phase 2 Not yet recruiting NCT04332380 [81 ] Convalescent plasma for patients with COVID-19: a randomized, open-label, parallel, controlled clinical study (CP-COVID-19) Plasma, hydroxychloroquine Phase 2/3 Not yet recruiting NCT04332835 [82 ] Antibodies Safety, tolerability, and pharmacokinetics of SAB-301 in healthy adults SAB-301, an antibody produced in cows to fight MERS Phase 1 Completed NCT02788188 [83 ] Antiviral drugs COVID-19 ring-based prevention trial with lopinavir/ritonavir (CORIPREV-LR) Lopinavir/ritonavir Phase 3 Recruiting NCT04321174 [84 ] Evaluating the efficacy of artesunate in adults with mild symptoms of COVID-19 Artemisinin/artesunate Phase 2 Not yet recruiting NCT04387240 [85 ] Hydroxychloroquine as chemoprevention for COVID-19 for high-risk healthcare workers Hydroxychloroquine sulfate (HCQ) Phase 2 Enrolling by invitation NCT04345653 [86 ] New antiviral drugs for treatment of COVID-19 Combination of nitazoxanide, ribavirin, and ivermectin Phase 3 Not yet recruiting NCT04392427 [87 ] Study to evaluate the safety and antiviral activity of remdesivir (GS-5734™) in participants with moderate coronavirus disease (COVID-19) compared to standard of care treatment Remdesivir Phase 3 Recruiting NCT04292730 [88 ] Adaptive COVID-19 Treatment Trial (ACTT) Remdesivir Phase 3 Recruiting NCT04280705 [89 ] Traditional Chinese medicine A real-world study for the efficacy and safety of large-dose Tanreqing injection in the treatment of patients with novel coronavirus pneumonia (COVID-19) Large-dose Tanreqing injection Phase 4 Not yet recruiting ChiCTR2000029432 [90 ] Clinical study for Gubiaojieduling in preventing of novel coronavirus pneumonia (COVID-19) in children Gubiaojieduling — Not yet recruiting ChiCTR2000029487 [91 ] Clinical trial for Tanreqing capsules in the treatment of novel coronavirus pneumonia (COVID-19) Tanreqing capsules Phase 0 Recruiting ChiCTR2000029813 [92 ] Shenfu injection in the treatment of severe novel coronavirus pneumonia (COVID-19): a multicenter, randomized, open-label, controlled trial Shenfu injection Phase 4 Not yet recruiting ChiCTR2000030043 [93 ] A multicenter, randomized, open-label, controlled trial for the efficacy and safety of Shenqi Fuzheng injection in the treatment of novel coronavirus pneumonia (COVID-19) Shenqi Fuzheng injection Phase 4 Recruiting ChiCTR2000029780 [94 ] A randomized, open-label, blank-controlled trial for Lianhua Qingwen capsule /granule in the treatment of novel coronavirus pneumonia (COVID-19) Lianhua Qingwen capsule/granule Phase 4 Completed ChiCTR2000029434 [95 ] A randomized, open-label, blank-controlled, multicenter trial for Shuang-Huang-Lian oral solution in the treatment of novel coronavirus pneumonia (COVID-19) Shuang-Huang-Lian oral solution Phase 4 Recruiting ChiCTR2000029605 [96 ] A randomized controlled trial for honeysuckle decoction in the treatment of patients with novel coronavirus (COVID-19) infection Honeysuckle soup Phase 0 Recruiting ChiCTR2000029822 [97 ] A multicenter, randomized, open-label, and controlled trial for the efficacy and safety of Kang-Bing-Du granules in the treatment of novel coronavirus pneumonia (COVID-19) Kang-Bing-Du granules Phase 4 Recruiting ChiCTR2000029781 [98 ] Efficacy and safety of Jing-Yin granule in the treatment of novel coronavirus pneumonia (COVID-19) wind-heat syndrome Jing-Yin granule Phase 4 Not yet recruiting ChiCTR2000030255 [99 ] A randomized, open-label, controlled trial for the safety and efficiency of Kesuting syrup and Keqing capsule in the treatment of mild and moderate novel coronavirus pneumonia (COVID-19) Kesuting syrup and Keqing capsule Phase 4 Recruiting ChiCTR2000029991 [100 ] A multicenter, randomized, open-label, parallel, controlled trial for the evaluation of the effectiveness and safety of Xiyanping injection in the treatment of common type novel coronavirus pneumonia (COVID-19) Xiyanping injection Phase 4 Recruiting ChiCTR2000030117 [101 ] Efficacy and safety of Xue-Bi-Jing injection in the treatment of severe cases of novel coronavirus pneumonia (COVID-19) Xue-Bi-Jing injection Phase 0 Recruiting ChiCTR2000030388 [102 ] Others Clinical application of methylene blue for treatment of COVID-19 patients (COVID-19) Methylene blue, vitamin C, N-acetyl cysteine (MCN) Phase 1 Recruiting NCT04370288 [103 ] NO prevention of COVID-19 for healthcare providers (NOpreventCOVID) Inhaled nitric oxide gas Phase 2 Not yet recruiting NCT04312243 [104 ] Angiotensin-(1,7) treatment in COVID-19: The ATCO Trial (ATCO) Angiotensin 1-7 (a peptide that is downregulated in COVID-19 patient and it may potentially improve respiratory function) Phase 2/3 Not yet recruiting NCT04332666 [105 ] Use of cSVF via IV deployment for residual lung damage after symptomatic COVID-19 infection (GARM-COVID19) IV deployment of cellular stromal vascular fraction (cSVF) in sterile normal saline IV solution Early phase 1 Enrolling by invitation NCT04326036 [106 ]
